Romiplostim for management of chemotherapy-induced thrombocytopenia
- 12 January 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 22 (5), 1217-1222
- https://doi.org/10.1007/s00520-013-2074-2
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Leukaemic transformation with romiplostimBritish Journal of Haematology, 2012
- Biology and Chemistry of Thrombopoietic AgentsSeminars in Hematology, 2010
- 9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding studyEuropean Journal of Cancer Supplements, 2009
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJama-Journal Of The American Medical Association, 2008
- How I treat venous thromboembolism in patients with cancerBlood, 2005
- Venous thromboembolism: disease burden, outcomes and risk factorsJournal of Thrombosis and Haemostasis, 2005
- Cancer and venous thromboembolismThe Lancet Oncology, 2005
- Recombinant human thrombopoietin: basic biology and evaluation of clinical studiesBlood, 2002
- Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopeniaSeminars in Hematology, 2000
- Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopeniaSeminars in Hematology, 2000